Skip to main content

Advertisement

SpringerLink
Log in

18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin’s lymphoma as predictors of treatment outcome and survival

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

A Publisher Correction to this article was published on 20 June 2018

This article has been updated

Abstract

Purpose

To determine whether metabolic tumor parameters and radiomic features extracted from 18F-FDG PET/CT (PET) can predict response to therapy and outcome in patients with aggressive B-cell lymphoma.

Methods

This institutional ethics board-approved retrospective study included 82 patients undergoing PET for aggressive B-cell lymphoma staging. Whole-body metabolic tumor volume (MTV) using various thresholds and tumor radiomic features were assessed on representative tumor sites. The extracted features were correlated with treatment response, disease-free survival (DFS) and overall survival (OS).

Results

At the end of therapy, 66 patients (80.5%) had shown complete response to therapy. The parameters correlating with response to therapy were bulky disease > 6 cm at baseline (p = 0.026), absence of a residual mass > 1.5 cm at the end of therapy CT (p = 0.028) and whole-body MTV with best performance using an SUV threshold of 3 and 6 (p = 0.015 and 0.009, respectively). None of the tumor texture features were predictive of first-line therapy response, while a few of them including GLNU correlated with disease-free survival (p = 0.013) and kurtosis correlated with overall survival (p = 0.035).

Conclusions

Whole-body MTV correlates with response to therapy in patient with aggressive B-cell lymphoma. Tumor texture features could not predict therapy response, although several features correlated with the presence of a residual mass at the end of therapy CT and others correlated with disease-free and overall survival. These parameters should be prospectively validated in a larger cohort to confirm clinical prognostication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

  • 20 June 2018

    In the original publication of the article, the title was incorrectly.

References

  1. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:3048–3058.

    Article  Google Scholar 

  2. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Malek E, Sendilnathan A, Yellu M, Petersen A, Fernandez-Ulloa M, Driscoll JJ. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. Blood Cancer J. 2015;5:e326.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology. 2016;21(2):99–105.

    PubMed  CAS  Google Scholar 

  5. Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22:3801–9.

    Article  PubMed  CAS  Google Scholar 

  7. Gevaert O, Xu J, Hoang CD, Leung AN, Xu Y, Quon A, et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data—methods and preliminary results. Radiology. 2012;264:387–96.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, et al. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology. 2014;270:464–71.

    Article  PubMed  Google Scholar 

  9. Diaz-Cano SJ. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci. 2012;13:1951–2011.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30:1234–48.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nioche C, Orlhac F, Soussan M, Boughdad S, Alberini J, Buvat I. A software for characterizing intra-tumor heterogeneity in multimodality imaging and establishing reference charts. Eur J Nucl Med Mol Imaging. 2016;43:S156-S157.

    Google Scholar 

  12. Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011;93:502–8.

    Article  PubMed  Google Scholar 

  13. Nguygen XC, Lee WW, Amin AM, Eo JS, Bang SM, Lee JS, et al. Tumor burden assessed by the maximum standardized uptake value and greatest diameter on FDG-PET predicts prognosis in untreated diffuse large B-cell lymphoma. Nucl Med Mol Imaging. 2010;44:39–44.

    Article  Google Scholar 

  14. Miyazaki Y, Nawa Y, Miyagawa M, Kohashi S, Nakase K, Yasukawa M, et al. Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma. Ann Hematol. 2013;92:239–44.

    Article  PubMed  CAS  Google Scholar 

  15. Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology. 2016;21:99–105.

    PubMed  CAS  Google Scholar 

  16. Boellaard R, O’Doherty MJ, Weber WA, Giammarile F, Tatsch K, Eschner W, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.

    Article  PubMed  Google Scholar 

  17. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, et al. Clinical implications of PET-negative residual CT masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2631–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Aatif Parvez and Noam Tau contributed equally to this study and to the manuscript.

Authors and Affiliations

  1. Joint Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Mount Sinai Hospital and Women’s College Hospital, University of Toronto, 610 University Ave, Suite 3-960, Toronto, ON, M5G 2M9, Canada

    Aatif Parvez, Noam Tau, Douglas Hussey & Ur Metser

  2. Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada

    Manjula Maganti

Authors
  1. Aatif Parvez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noam Tau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas Hussey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manjula Maganti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ur Metser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ur Metser.

Additional information

The original version of this article was revised: The article title was corrected.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 14 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parvez, A., Tau, N., Hussey, D. et al. 18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin’s lymphoma as predictors of treatment outcome and survival. Ann Nucl Med 32, 410–416 (2018). https://doi.org/10.1007/s12149-018-1260-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-018-1260-1

Keywords

Search

Navigation